EDAP Ablatherm-HIFU Strongly Highlighted in European CongressesLYON, France, June 18 /PRNewswire-FirstCall/ -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, reports continued and sustained marketing presence in various European events to grow Ablatherm-HIFU market penetration all over Europe.

In the month of June, EDAP participated in three major Urology events in Europe to promote Ablatherm-HIFU treatment for patients with localized prostate cancer.

EDAP and its Spanish distributor Davanzia were present at the Annual Congress of the Spanish Urological Association, at La Coruna. They jointly organized an Ablatherm-HIFU Symposium chaired by Dr. Fernando Gomez Sancha, from the "Instituto de Cirugia Urologica Avanzada," Madrid, Spain, who began using the company's device after careful review of all HIFU options in November 2006.

"The recent Symposium at the Annual Congress of the Spanish Urological Association covered the aspects HIFU and the initial Spanish success at centers in Madrid and Bilbao," said Dr. Gomez Sancha. "Dr. Sebastian Rogenhofer from Regensburg University Hospital, Germany, presented his overwhelming long term experience as well affirming the clinical strength of Ablatherm-HIFU, the only device with such proven long term experience. The uptake of HIFU in Spain has been very rapid, with eight centers now offering the technique nationwide. This rapid adoption is partly explained by the fact that EDAP has a very strict training policy on Ablatherm-HIFU, and doctors feel it is safe for their patients to start using the system."

Dr. Gomez Sancha continued, "Several features of Ablatherm-HIFU were stressed during the Symposium including that EDAP's Ablatherm-HIFU is a very sophisticated and precise truly robotic system, with many built-in safety features. Also, ten years of follow up data demonstrate that HIFU is an effective and safe technique for the treatment of localized prostate cancer under these protocols."

Early June, EDAP also attended the Portuguese National Congress of Urology held in Vilamoura, gathering all Urologists from Portugal. Dr. Chris d'Hont, from Middelheim Hospital, in Antwerpen, Belgium, presented the benefits of Ablatherm-HIFU as an option for localized prostate cancer and its superiority compared to existing techniques such as cryotherapy and brachytherapy.

Also, mid-June, EDAP actively participated in the Annual Scandinavian Congress of Urology held in Aarhus, Denmark. Aker Hospital's team in Norway, Dr. Berge and Dr. Baco, whose Urology Dept is headed by Pr. Karlsen, presented their results obtained using Ablatherm-HIFU. They reported low and very acceptable side effects associated with the treatment. They concluded that Ablatherm-HIFU is a valid option for localized prostate cancer and particularly on patients who failed radiotherapy.

Jean-Francois Bachelard, Business Unit Director for Northern Europe, commented: "I am very excited on the development of Ablatherm-HIFU in Europe. We clearly see interest in the urology community to offer HIFU therapy to patients with prostate cancer. Aker's Hospital has been using our Ablatherm-HIFU for more than one year on an RPP fixed basis and it recently decided to acquire the device. The team of urologists has been convinced of Ablatherm's benefits and concluded it is valuable adding this option to their range of therapies for prostate cancer for their patient's best interest."

"We are very pleased with the success we are enjoying through our relationship with top distributors in Europe, including Davanzia in the Spanish market, Dico Company in Scandinavia and Hemoportugal in Portugal," said Oczachowski. "EDAP has successfully developed along the years a strong and active network of professionals all over Europe, based on track records of successes in the Healthcare field and on long term relationships built by our partners with the local medical community. EDAP's distributors, supported by our direct sales team, are fully committed to expand Ablatherm-HIFU business."

About EDAP TMS S.A.

EDAP TMS S.A. develops and markets Ablatherm, the most advanced and clinically proven choice for High Intensity Focused Ultrasound (HIFU) treatment of localized prostate cancer. HIFU treatment is shown to be a minimally invasive and effective treatment option with a low occurrence of side effects. Ablatherm-HIFU is generally recommended for patients with localized prostate cancer (stages T1-T2) who are not candidates for surgery or who prefer an alternative option, or for patients who failed radiotherapy treatment. The company is also developing this technology for the potential treatment of certain other types of tumors. EDAP TMS S.A. also produces and commercializes medical equipment for treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL).

For more information on the Company, contact Magnolia Investor Relations at (972) 801-4900, the Corporate Investor Relations Dept at +33 (0)4 78 26 40 46 or see the Company's Web sites at http://www.edap-tms.com and http://www.hifu-planet.com.

To sign up for alerts please visithttp://www.b2i.us/irpass.asp?BzID=1053&to=ea&s=0

In addition to historical information, this press release contains forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in these forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission. Ablatherm-HIFU treatment is in clinical trials but not yet FDA approved or marketed in the United States.

CONTACT: EDAP TMS S.A. Magnolia Investor Relations

               Blandine Confort      Matt Kreps
               +33 4 78 26 40 46     972 801 4900

SOURCE EDAP TMS S.A.